WO2006110577A3 - Methodes et compositions pour reduire la production de cytokines pro-inflammatoires - Google Patents

Methodes et compositions pour reduire la production de cytokines pro-inflammatoires Download PDF

Info

Publication number
WO2006110577A3
WO2006110577A3 PCT/US2006/013149 US2006013149W WO2006110577A3 WO 2006110577 A3 WO2006110577 A3 WO 2006110577A3 US 2006013149 W US2006013149 W US 2006013149W WO 2006110577 A3 WO2006110577 A3 WO 2006110577A3
Authority
WO
WIPO (PCT)
Prior art keywords
fril
proteins
pro
inflammatory cytokines
production
Prior art date
Application number
PCT/US2006/013149
Other languages
English (en)
Other versions
WO2006110577A2 (fr
Inventor
Charles A Dinarello
Jeffrey G Moore
Original Assignee
Morningside Venture Invest Ltd
Charles A Dinarello
Jeffrey G Moore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morningside Venture Invest Ltd, Charles A Dinarello, Jeffrey G Moore filed Critical Morningside Venture Invest Ltd
Priority to EP06740758A priority Critical patent/EP1901766A2/fr
Priority to CA002604007A priority patent/CA2604007A1/fr
Priority to AU2006235254A priority patent/AU2006235254A1/en
Publication of WO2006110577A2 publication Critical patent/WO2006110577A2/fr
Publication of WO2006110577A3 publication Critical patent/WO2006110577A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne l'utilisation de protéines de la famille FRIL (ligand en interaction avec le récepteur de FTL3), les protéines FRIL peuvent s'utiliser dans des méthodes de traitement de maladies inflammatoires, qui sont caractérisées par des taux indésirables de cytokines pro-inflammatoires, ainsi que dans la fabrication de médicaments utilisés dans le traitement de telles maladies. Les maladies inflammatoires pouvant être traitées par les protéines FRIL comprennent, sans limitation: les troubles auto-immuns, les maladies neurodégénératives et les cancers. Les protéines FRIL de l'invention peuvent en outre s'utiliser comme thérapie complémentaire pour augmenter la tolérance chez des patients faisant l'objet de transplantations.
PCT/US2006/013149 2005-04-08 2006-04-07 Methodes et compositions pour reduire la production de cytokines pro-inflammatoires WO2006110577A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP06740758A EP1901766A2 (fr) 2005-04-08 2006-04-07 Methodes et compositions pour reduire la production de cytokines pro-inflammatoires
CA002604007A CA2604007A1 (fr) 2005-04-08 2006-04-07 Methodes et compositions pour reduire la production de cytokines pro-inflammatoires
AU2006235254A AU2006235254A1 (en) 2005-04-08 2006-04-07 Use of FRIL proteins for reducing the production of pro-inflammatory cytokines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66941805P 2005-04-08 2005-04-08
US60/669418 2005-04-08

Publications (2)

Publication Number Publication Date
WO2006110577A2 WO2006110577A2 (fr) 2006-10-19
WO2006110577A3 true WO2006110577A3 (fr) 2007-05-18

Family

ID=36968339

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/013149 WO2006110577A2 (fr) 2005-04-08 2006-04-07 Methodes et compositions pour reduire la production de cytokines pro-inflammatoires

Country Status (4)

Country Link
EP (1) EP1901766A2 (fr)
AU (1) AU2006235254A1 (fr)
CA (1) CA2604007A1 (fr)
WO (1) WO2006110577A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2265265A2 (fr) * 2008-03-10 2010-12-29 The Charlotte-Mecklenburg Hospital Authority Traitement des affections et maladies inflammatoires au moyen de métal-thiols
CN101690801B (zh) * 2009-10-26 2012-08-01 上海交通大学 白细胞介素-1受体拮抗剂的用途及其药物组合物
US20120094931A1 (en) * 2010-06-30 2012-04-19 Collins Colm Compositions and methods to modulate progression and onset of inflammatory bowel disease
KR20120093002A (ko) * 2011-02-14 2012-08-22 (주)에이티젠 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트
US20210386820A1 (en) * 2018-09-06 2021-12-16 Academia Sinica Antiviral lectin and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049851A1 (fr) * 1999-12-30 2001-07-12 Phylogix Llc Facteurs de conservation de cellules souches, procedes et produits s'y rapportant
WO2005046613A2 (fr) * 2003-11-12 2005-05-26 Morningside Venture Investments Limited Procedes et compositions pour le traitement des lymphomes des lymphocytes b et d'autres cancers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049851A1 (fr) * 1999-12-30 2001-07-12 Phylogix Llc Facteurs de conservation de cellules souches, procedes et produits s'y rapportant
WO2005046613A2 (fr) * 2003-11-12 2005-05-26 Morningside Venture Investments Limited Procedes et compositions pour le traitement des lymphomes des lymphocytes b et d'autres cancers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOORE^A J G ET AL: "A new lectin in red kidney beans called PvFRIL stimulates proliferation of NIH 3T3 cells expressing the Flt3 receptor", BIOCHIMICA ET BIOPHYSICA ACTA - GENERAL SUBJECTS, ELSEVIER SCIENCE PUBLISHERS, NL, vol. 1475, no. 3, 26 July 2000 (2000-07-26), pages 216 - 224, XP004276640, ISSN: 0304-4165 *

Also Published As

Publication number Publication date
EP1901766A2 (fr) 2008-03-26
WO2006110577A2 (fr) 2006-10-19
AU2006235254A1 (en) 2006-10-19
CA2604007A1 (fr) 2006-10-19

Similar Documents

Publication Publication Date Title
MX2007004551A (es) Compuestos tiadiazol y metodos de uso.
WO2006058868A3 (fr) Pteridines substituees destinees au traitement de maladies inflammatoires
MY149606A (en) Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
WO2009050506A3 (fr) Combinaison 059
UA101493C2 (ru) Производные азетидина и циклобутана как ингибиторы jak
AU2012277802A8 (en) Novel inhibitor compounds of phosphodiesterase type 10A
WO2006058867A3 (fr) Pteridines substituees pour le traitement de maladies inflammatoires
WO2006035204A3 (fr) Polytherapie
CR20190563A (es) Imidazopirimidinas diazabicíclicas sustituidas y su uso para el tratamiento de trastornos respitatorios
WO2009131712A3 (fr) Lymphocytes b régulateurs et leurs applications
MX2007003506A (es) Terapia de combinacion de cancer que comprende azd2171 e imatinib.
MX272108B (es) Heterociclos sustituidos.
WO2007135026A3 (fr) Ptéridines substituées
WO2007071958A3 (fr) Therapie combinee
WO2006110577A3 (fr) Methodes et compositions pour reduire la production de cytokines pro-inflammatoires
HK1123976A1 (en) Combination of azd2171 and pemetrexed azd2171
CR20210499A (es) Compuestos y composiciones como moduladores de la señalización de tlr
CR20230177A (es) Compuestos y composiciones como moduladores de señalización tlr
WO2007003933A3 (fr) Polytherapie
TW200635920A (en) Pyrazinedicarboxamides and their use
DE602004016754D1 (de) Kombinationstherapie gegen krebserkrankungen mit azd2171 und zd1839
WO2020140021A3 (fr) Procédé de production, d'isolement et de purification de protéines recombinantes modifiées
WO2023192885A3 (fr) Procédés d'utilisation de composés oligomères pour traiter des troubles liés au scn2a
WO2005058235A3 (fr) Methodes utilisant le sulodexide dans le traitement des maladies de la vessie

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2604007

Country of ref document: CA

Ref document number: 2008505597

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 2006235254

Country of ref document: AU

Ref document number: 2006740758

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006235254

Country of ref document: AU

Date of ref document: 20060407

Kind code of ref document: A